DMAA

+ Watchlist + Portfolio

Drugs Made In America Acquisition Corp.

Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $10.89
52-Week Range: $10.26 – $10.89
Market Cap: $264.29M
P/E (TTM): 60.48
EPS (TTM): 0.18
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.02
Debt/Equity: —
Total Debt: $350.00K
Free Cash Flow: —
Revenue Growth: —
Earnings Growth: -17.90%
Enterprise Value: $264.71M

DMAA Income statement, annual periods, in USD
USD	FY2025
Revenue	$0.00
Selling, General & Admin	$2.82M
Operating Expenses	$2.82M
Operating Income	-$2.82M
EBITDA	-$2.82M
Pretax Income	$5.94M
Net Income	$5.94M
Diluted EPS	0.19
Diluted Shares	31.64M

DMAA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Selling, General & Admin	$330.93K	$131.92K	$263.70K	$2.09M	$143.30K	$136.93K
Operating Expenses	$330.93K	$131.92K	$263.70K	$2.09M	$143.30K	$136.93K
Operating Income	-$330.93K	-$131.92K	-$263.70K	-$2.09M	-$143.30K	-$136.93K
EBITDA	-$330.93K	-$131.92K	-$263.70K	-$2.09M	-$143.30K	-$136.93K
Pretax Income	$1.25M	$2.29M	$2.18M	$212.96K	$1.97M	$1.73M
Net Income	$1.25M	$2.29M	$2.18M	$212.96K	$1.97M	$1.73M
Diluted EPS	0.05	0.07	0.07	—	0.06	0.06
Diluted Shares	25.51M	33.52M	33.52M	—	33.72M	30.81M

DMAA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$923.00	$822.00	$717.00	$6.14K	$14.89K	$20.28K
Current Assets	$71.02K	$49.73K	$28.20K	$12.19K	$14.89K	$69.18K
Total Assets	$232.81M	$235.21M	$237.63M	$239.92M	$242.04M	$146.90M
Current Liabilities	$347.37K	$301.44K	$456.61K	$376.17K	$492.17K	$2.94M
Total Debt	$60.90K	—	—	—	$100.00K	$950.00K
Total Liabilities	$7.25M	$7.20M	$7.36M	$7.28M	$7.39M	$9.14M
Retained Earnings	-$6.33M	-$6.46M	-$6.72M	-$7.27M	-$7.38M	-$7.41M
Shareholders' Equity	$225.56M	$228.00M	$230.28M	$232.64M	$234.64M	$137.77M
Working Capital	-$276.35K	-$251.72K	-$428.42K	-$363.98K	-$477.28K	-$2.88M
Net Debt	$59.98K	—	—	—	$85.11K	$929.72K

DMAA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$251.24K	-$106.66K	-$56.11K	-$125.18K	-$91.25K	-$244.61K
Free Cash Flow	-$251.24K	-$106.66K	-$56.11K	-$125.18K	-$91.25K	-$244.61K
Investing Cash Flow	-$231.15M	$0.00	$0.00	$0.00	$0.00	$98.71M
Financing Cash Flow	$231.40M	$106.55K	$56.00K	$130.60K	$100.00K	-$98.46M
Net Change in Cash	-$428.00	-$101.00	-$105.00	$5.42K	$8.75K	$5.39K

Market Snapshot

About

Drugs Made In America Acquisition Corp. is a special purpose acquisition company (SPAC) formed to identify and merge with a target business in the pharmaceutical or healthcare manufacturing sector. The company's stated focus is on businesses involved in reshoring pharmaceutical production to the United States. Like all SPACs, Drugs Made In America has a limited timeframe to complete a business combination or return capital to shareholders. Until a merger is completed, the company holds investor proceeds in trust.

USD	FY2025
Operating Cash Flow	-$539.19K
Free Cash Flow	-$539.19K
Investing Cash Flow	-$231.15M
Financing Cash Flow	$231.69M
Net Change in Cash	$4.79K